No profile data available.
Tenax Therapeutics, Inc. (TENX) is a healthcare company in the blood vessel treatment pharmaceuticals industry, based in Chapel Hill, United States, with about 14 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$52.60 million. Europe was its largest region in fiscal year 2013, with 50% of revenue. Its market capitalization was $69.98 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a development-stage pharmaceutical company, develops novel cardiopulmonary therapies in the United States.
Tenax Therapeutics reported $0 in revenue for fiscal year 2025.
Europe: 50% of revenue by region in fiscal year 2013, followed by United States (50%).
$69.98 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood vessel treatment pharmaceuticals) include Gossamer Bio, Inc. (GOSS), Tectonic Therapeutic, Inc. (TECX), DiaMedica Therapeutics Inc. (DMAC), Grace Therapeutics, Inc. (GRCE).